News and Trends 17 Sep 2025 Budget blues: where are cell and gene therapies heading? …through clinical trial application (CTA)-ready status in Europe, and we are now preparing a larger series A to enable our first-in-human trial in Alzheimer’s,” said Lucio. “Despite the macro headwinds,… September 17, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2018 International Fund Raises €300M for Dementia Research …is dedicated to investing in early-stage ventures that develop disease-modifying therapeutics for all types of dementia, including Alzheimer’s and Parkinson’s. Yesterday, the DDF completed a $350 (€300M) fundraising that far… June 27, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 5 Dec 2022 The biggest private biotech investments in November 2022 …progress of Alzheimer’s disease by targeting harmful tangles of a protein called tau in the brain. According to TauRx, the large fundraise was in part fueled by the announcement of… December 5, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2025 Top biotech deals of December 2024 …antibody program, which consists of BAN1503 and BAN2803, for Alzheimer’s disease. PyroGlu-Aβ is highly prone to aggregate and cause the cognitive symptoms associated with Alzheimer’s disease. BioArctic will cash in… January 16, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Jun 2024 5 companies spearheading the emerging biotech scene in the Balkans …development of novel, proprietary, blood-brain barrier permeable small molecules for the treatment of neuroinflammatory and neurodegenerative diseases, such as diabetic retinopathy, demyelination and multiple sclerosis (MS), Parkinson’s and Alzheimer’s disease. … June 18, 2024 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Weekly Roundup 8 Dec 2023 Xenon’s $345 million public offering; EyePoint Pharmaceuticals’ trial success; gene therapy found to reduce liver cancer …endpoint misses statistical significance in BioVie’s trial of Alzheimer’s disease treatment Last week, BioVie announced positive analysis of unblinded, topline efficacy data from its phase 3 clinical trial of NE3107… December 8, 2023 - 14 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 9 Dec 2019 As Big Pharma Abandons Neuroscience, Can Biotech Provide Answers? …all other drugs. Clinical trials in neuroscience, and particularly in neurodegenerative conditions such as Alzheimer’s and Parkinson’s, also tend to be large and complex. This means they usually take longer… December 9, 2019 - 9 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Health Awareness Days …Day June Myasthenia gravis awareness month Alzheimer’s and brain awareness month Antiphospholipid Antibody Syndrome Awareness Month Cancer from the Sun Month Cataract Awareness Month Child Vision Awareness Month National Aphasia… November 24, 2022 - 1 minutemin - By Aurore Michelin Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 Research identifies new treatment target for CNS injury and neurological disease Researchers in Birmingham in the U.K. have identified a potential target for drugs to treat long-term neurological conditions like Alzheimer’s Disease and foster nerve regeneration in central nervous system injuries…. September 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2023 2023 Editorial Calendar updated …the field – what it is, what it can address, and how the future of cell and gene therapy research looks. June 14: Alzheimer’s and Brain Awareness Month This special… January 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2023 SandboxAQ launches new division to boost drug development …in treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. The company is currently working with biopharma companies and university research labs, including AstraZeneca, Sanofi and UC San Francisco. Paul Hudson,… June 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023 JPND launches €16.5M call for research on OMICS data for neurodegenerative diseases …Neurodegenerative diseases are debilitating and largely untreatable conditions that are strongly linked with age. Worldwide, there are estimated to be 50 million people with Alzheimer’s disease and related disorders. This… January 12, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email